重度哮喘精准治疗的研究进展

doi:10.12114/j.issn.1007-9572.2019.00.662

摘要/Abstract

摘要： 重度哮喘患者急性发作频率高，具有较高的病死率，消耗着巨大的医疗卫生资源。目前以糖皮质激素为主的治疗方案对于重度哮喘患者效果有限且具有较大的不良反应，临床上亟须探索新的治疗方式。目前学术界认识到哮喘是一种异质性疾病，根据其病理机制可分为Th2型哮喘与非Th2型哮喘，通过一系列生物标志物的评估确定患者的内在型，进而选择合适的针对各靶点的单克隆抗体治疗，即精准治疗，在重度哮喘的治疗中展现出良好的应用前景。本文就哮喘的内在型分型及相对应的精准治疗做一系统阐述，旨在为重度哮喘的临床治疗提供参考。

关键词: 哮喘；精准治疗；内在型；表型；抗体, 单克隆

Abstract: Patients with severe asthma have increased risk of exacerbations and morbidities with more healthcare costs.The glucocorticoid-based therapy in severe asthma is not satisfactory with several side effects.There is an agent need for a new therapy.Asthma is a disease with marked heterogeneity and can be divided into two endotypes depending on the pathological mechanism：T helper 2 Asthma and non-T helper 2 Asthma.Precision therapy is to identify a specific endotype through a complete evaluation of all available biomarkers and make a correct selection of monoclonal antibody targeted specific molecules，which has a promising outlook in the treatment of severe asthma.In this review，we discuss the endotypes and the related precision therapy in severe asthma in order to make a reference for the clinical practice.

Key words: Asthma；Precision therapy；Endotypes；Phenotypes；Antibodies, monoclonal

杨宏宽. 重度哮喘精准治疗的研究进展[J]. 中国全科医学, 2020, 23(15): 1843-1848. DOI: 10.12114/j.issn.1007-9572.2019.00.662.
YANG Hongkuan. Advances in Research on Precision Therapy in Asthma Treatment　[J]. Chinese General Practice, 2020, 23(15): 1843-1848. DOI: 10.12114/j.issn.1007-9572.2019.00.662.

参考文献

［1］CHUNG K F，WENZEL S E，BROZEK J L，et al．International ERS/ATS guidelines on definition，evaluation and treatment of severe asthma［J］．Eur Respir J，2014，43（2）：343-373.DOI：10.1183/09031936.00202013.
［2］VOLMER T，EFFENBERGER T，TRAUTNER C，et al．Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults：a focused review of the impact data in the literature［J］．Eur Respir J，2018，52（4）：1800703.DOI：10.1183/13993003.00703-2018.
［3］DE BENEDICTIS F M，BUSH A.Corticosteroids in respiratory diseases in children［J］．Am J Respir Crit Care Med，2012，185（1）：12-23.DOI：10.1164/rccm.201107-1174ci.
［4］WENZEL S E.Asthma phenotypes：the evolution from clinical to molecular approaches［J］．Nat Med，2012，18（5）：716-725.DOI：10.1038/nm.2678.
［5］CARR T F，BLEECKER E.Asthma heterogeneity and severity［J］．World Allergy Organ J，2016，9（1）：41.DOI：10.1186/s40413-016-0131-2.
［6］CHUNG K F，ADCOCK I M.Precision medicine for the discovery of treatable mechanisms in severe asthma［J］．Allergy，2019.DOI：10.1111/all.13771.
［7］SANTUS P，SAAD M，DAMIANI G，et al．Current and future targeted therapies for severe asthma：managing treatment with biologics based on phenotypes and biomarkers［J］．Pharmacol Res，2019，146：104296.DOI：10.1016/j.phrs.2019.104296.
［8］Global Initiative for Asthma.Global strategy for asthma management and prevention 2019［EB/OL］．［2019-03-14］．http：//www.ginasthma.org.
［9］HUMBERT M，BEASLEY R，AYRES J，et al．Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy （GINA 2002 step 4 treatment）：INNOVATE［J］．Allergy，2005，60（3）：309-316.DOI：10.1111/j.1398-9995.2004.00772.x.
［10］NORMANSELL R，WALKER S，MILAN S J，et al．Omalizumab for asthma in adults and children［J］．Cochrane Database Syst Rev，2014（1）：CD003559.DOI：10.1002/14651858.CD003559.pub4.
［11］HANANIA N A，ALPAN O，HAMILOS D L，et al．Omalizumab in severe allergic asthma inadequately controlled with standard therapy：a randomized trial［J］．Ann Intern Med，2011，154（9）：573-582.DOI：10.7326/0003-4819-154-9-201105030-00002.
［12］CHEN H，EISNER M D，HASELKORN T，et al．Concomitant asthma medications in moderate-to-severe allergic asthma treated with omalizumab［J］．Respir Med，2013，107（1）：60-67.DOI：10.1016/j.rmed.2012.09.008.
［13］BRAUNSTAHL G J，CHLUMSKY J，PEACHEY G，et al．Reduction in oral corticosteroid use in patients receiving omalizumab for allergic asthma in the real-world setting［J］．Allergy Asthma Clin Immunol，2013，9（1）：47.DOI：10.1186/1710-1492
-9-47.
［14］HANANIA N A，WENZEL S，ROSéN K，et al．Exploring the effects of omalizumab in allergic asthma：an analysis of biomarkers in the EXTRA study［J］．Am J Respir Crit Care Med，2013，187（8）：804-811.DOI：10.1164/rccm.201208-1414OC.
［15］DI BONA D，FIORINO I，TAURINO M，et al．Long-term “real-life” safety of omalizumab in patients with severe uncontrolled asthma：a nine-year study［J］．Respir Med，2017，130：55-60.DOI：10.1016/j.rmed.2017.07.013.
［16］LONG A D，RAHMAOUI A，ROTHMAN K J，et al．Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab［J］．J Allergy Clin Immunol，2014，134（3）：560-567.e4.DOI：10.1016/j.jaci.2014.02.007.
［17］GAUVREAU G M，ARM J P，BOULET L P，et al．Efficacy and safety of multiple doses of QGE031 （ligelizumab） versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses［J］．J Allergy Clin Immunol，2016，138（4）：1051-1059.DOI：10.1016/j.jaci.2016.02.027.
［18］KANDA A，DRISS V，HORNEZ N，et al．Eosinophil-derived IFN-gamma induces airway hyperresponsiveness and lung inflammation in the absence of lymphocytes［J］．J Allergy Clin Immunol，2009，124（3）：573-582.DOI：10.1016/j.jaci.2009.04.031.
［19］MENZELLA F，LUSUARDI M，GALEONE C，et al．Mepolizumab for severe refractory eosinophilic asthma：evidence to date and clinical potential［J］．Ther Adv Chronic Dis，2016，7（6）：260-277.DOI：10.1177/2040622316659863.
［20］NAIR P，PIZZICHINI M M M，KJARSGAARD M，et al．Mepolizumab for prednisone-dependent asthma with sputum eosinophilia［J］．N Engl J Med，2009，360（10）：985-993.DOI：10.1056/nejmoa0805435.
［21］HALDAR P，BRIGHTLING C E，HARGADON B，et al．Mepolizumab and exacerbations of refractory eosinophilic asthma［J］．N Engl J Med，2009，360（10）：973-984.DOI：10.1056/NEJMoa0808991.
［22］PRAZMA C M，WENZEL S，BARNES N，et al．Characterisation of an OCS-dependent severe asthma population treated with mepolizumab［J］．Thorax，2014，69（12）：1141-1142.DOI：10.1136/thoraxjnl-2014-205581.
［23］PAVORD I D，KORN S，HOWARTH P，et al．Mepolizumab for severe eosinophilic asthma （DREAM）：a multicentre，double-blind，placebo-controlled trial［J］．Lancet，2012，380（9842）：651-659.DOI：10.1016/S0140-6736（12）60988-X.
［24］BEL E H，WENZEL S E，THOMPSON P J，et al．Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma［J］．N Engl J Med，2014，371（13）：1189-1197.DOI：10.1056/NEJMoa1403291.
［25］LUGOGO N，DOMINGO C，CHANEZ P，et al．Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma：a multi-center open-label，phaseⅢb study［J］．Clin Ther，2016，38（9）：2058-2070.e1.DOI：10.1016/j.clinthera.2016.07.010.
［26］MARKHAM A.Reslizumab：first global approval［J］．Drugs，2016，76（8）：907-911.DOI：10.1007/s40265-016-0583-2.
［27］CASTRO M，MATHUR S，HARGREAVE F，et al．Reslizumab for poorly controlled，eosinophilic asthma：a randomized，placebo-controlled study［J］．Am J Respir Crit Care Med，2011，184（10）：1125-1132.DOI：10.1164/rccm.201103-0396OC.
［28］VIRCHOW J C，KATIAL R，BRUSSELLE G，et al．Safety of reslizumab in uncontrolled asthma with eosinophilia：a pooled analysis from six trials［J］．J Allergy Clin Immunol Pract，2019：S2213-2198（19）30701-9.DOI：10.1016/j.jaip.2019.07.038.
［29］CASTRO M，ZANGRILLI J，WECHSLER M E.Corrections.Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts：results from two multicentre，parallel，double-blind，randomised，placebo-controlled，phase 3 trials［J］．Lancet Respir Med，2015，3（4）：e15.DOI：10.1016/S2213-2600（15）00119-8.
［30］MASELLI D J，VELEZ M I，ROGERS L.Reslizumab in the management of poorly controlled asthma：the data so far［J］．J Asthma Allergy，2016，9：155-162.DOI：10.2147/JAA.S94164.
［31］PHAM T H，DAMERA G，NEWBOLD P，et al．Reductions in eosinophil biomarkers by benralizumab in patients with asthma［J］．Respir Med，2016，111：21-29.DOI：10.1016/j.rmed.2016.01.003.
［32］LAVIOLETTE M，GOSSAGE D L，GAUVREAU G，et al．Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia［J］．J Allergy Clin Immunol，2013，132（5）：1086-1096.e5.DOI：10.1016/j.jaci.2013.05.020.
［33］CASTRO M，WENZEL S E，BLEECKER E R，et al．Benralizumab，an anti-interleukin 5 receptor α monoclonal antibody，versus placebo for uncontrolled eosinophilic asthma：a phase 2b randomised dose-ranging study［J］．Lancet Respir Med，2014，2（11）：879-890.DOI：10.1016/S2213-2600（14）70201-2.
［34］BLEECKER E R，FITZGERALD J M，CHANEZ P，et al．Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists （SIROCCO）：a randomised，multicentre，placebo-controlled phase 3 trial［J］．Lancet，2016，388（10056）：2115-2127.DOI：10.1016/S0140-6736（16）31324-1.
［35］FITZGERALD J M，BLEECKER E R，NAIR P，et al．Benralizumab，an anti-interleukin-5 receptor α monoclonal antibody，as add-on treatment for patients with severe，uncontrolled，eosinophilic asthma （CALIMA）：a randomised，double-blind，placebo-controlled phase 3 trial［J］．Lancet，2016，388（10056）：2128-2141.DOI：10.1016/S0140-6736（16）31322-8.
［36］FERGUSON G T，FITZGERALD J M，BLEECKER E R，et al．Benralizumab for patients with mild to moderate，persistent asthma （BISE）：a randomised，double-blind，placebo-controlled，phase 3 trial［J］．Lancet Respir Med，2017，5（7）：568-576.DOI：10.1016/S2213-2600（17）30190-X.
［37］PERKINS C，WILLS-KARP M，FINKELMAN F D.IL-4 induces IL-13-independent allergic airway inflammation［J］．J Allergy Clin Immunol，2006，118（2）：410-419.DOI：10.1016/j.jaci.2006.06.004.
［38］SAHA S K，BERRY M A，PARKER D，et al．Increased sputum and bronchial biopsy IL-13 expression in severe asthma［J］．J Allergy Clin Immunol，2008，121（3）：685-691.DOI：10.1016/j.jaci.2008.01.005.
［39］WENZEL S，FORD L，PEARLMAN D，et al．Dupilumab in persistent asthma with elevated eosinophil levels［J］．N Engl J Med，2013，368（26）：2455-2466.DOI：10.1056/NEJMoa1304048.
［40］BUSSE W W，MASPERO J F，RABE K F，et al．Liberty asthma QUEST：phase 3 randomized，double-blind，placebo-controlled，parallel-group study to evaluate dupilumab efficacy/safety in patients with uncontrolled，moderate-to-severe asthma［J］．Adv Ther，2018，35（5）：737-748.DOI：10.1007/s12325-018-0702-4.
［41］CORREN J，BUSSE W，MELTZER E O，et al．A randomized，controlled，phase 2 study of AMG 317，an IL-4 Ralpha antagonist，in patients with asthma［J］．Am J Respir Crit Care Med，2010，181（8）：788-796.DOI：10.1164/rccm.200909-1448OC.
［42］CORREN J，LEMANSKE R F，HANANIA N A，et al．Lebrikizumab treatment in adults with asthma［J］．N Engl J Med，2011，365（12）：1088-1098.DOI：10.1056/nejmoa1106469.
［43］HANANIA N A，KORENBLAT P，CHAPMAN K R，et al．Efficacy and safety of lebrikizumab in patients with uncontrolled asthma （LAVOLTA I and LAVOLTA II）：replicate，phase 3，randomised，double-blind，placebo-controlled trials［J］．Lancet Respir Med，2016，4（10）：781-796.DOI：10.1016/S2213-2600（16）30265-X.
［44］PIPER E，BRIGHTLING C，NIVEN R，et al．A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma［J］．Eur Respir J，2013，41（2）：330-338.DOI：10.1183/09031936.00223411.
［45］BRIGHTLING C E，CHANEZ P，LEIGH R，et al．Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma：a randomised，double-blind，placebo-controlled，phase 2b trial［J］．Lancet Respir Med，2015，3（9）：692-701.DOI：10.1016/S2213-2600（15）00197-6.
［46］SZE E，BHALLA A，NAIR P.Mechanisms and therapeutic strategies for non-T2 asthma［J］．Allergy，2019.DOI：10.1111/all.13985.
［47］NAIR P，GAGA M，ZERVAS E，et al．Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils：a randomized，placebo-controlled clinical trial［J］．Clin Exp Allergy，2012，42（7）：1097-1103.DOI：10.1111/j.1365-2222.2012.04014.x.
［48］BUSSE W W，HOLGATE S，KERWIN E，et al．Randomized，double-blind，placebo-controlled study of brodalumab，a human anti-IL-17 receptor monoclonal antibody，in moderate to severe asthma［J］．Am J Respir Crit Care Med，2013，188（11）：1294-1302.DOI：10.1164/rccm.201212-2318OC.